The authors suggest that multi-site inhibitory interactions across synuclein chains may be critical for therapeutic development, but this remains an open translational challenge. Successfully addressing this could lead to novel Parkinson's disease treatments that mimic natural protective mechanisms. Gap type: open_question Source paper: Multi-Pronged Interactions Underlie Inhibition of α-Synuclein Aggregation by β-Synuclein. (2018, Journal of molecular biology, PMID:29782835)
Landscape Summary: Can therapeutic agents be designed to replicate β-synuclein's multi-domain inhibitory mechanism? is a 0.75 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Can therapeutic agents be designed to replicate β-synuclein's multi-domain inhibitory mechanism? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: